Cabergoline, 5000mcg, (50mcg/100tabs)
$139.95 If paid in BTC $111.96
Cabergoline, 5000mcg, (50mcg/100tabs)
Total amount of active ingredient: 50mcg
Quantity: 100 tabs
Shelf Life: 36 months
Packaging: Capsulated and in Mylar Bags
Label: 7.5cm x 2.8cm
•USA: $6.95 (3-7 business days)
•Canda: $13.95 (3-7 business days)
•International: $18.95 (7-14 business days)
•Europe: $15.95 (7-14 business days)
•South Asia: (Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, Sri Lanka) $63.95 (7-14 business days) Not available at this time
•Middle Eastern: (Egypt, Bahrain, Cyprus, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Syria, UAE, Yemen, Turkey): $58.95 (7-14 business days)
If your shipment was seized (International Orders), we will provide a 50% discount applicable on your next purchase. Please contact us for more information.
Products are made and housed in the USA and Europe.
Cabergoline, an ergot subordinate, is an incredible dopamine receptor agonist on D2 receptors. Rodent considers show cabergoline has a direct inhibitory impact on pituitary lactotroph (prolactin) cells. It is oftentimes utilized as a first-line specialist in the administration of prolactinomas because of its higher partiality for D2 receptor destinations, less serious reactions, and increasingly advantageous dosing schedule than the older bromocriptine, though in pregnancy bromocriptine is regularly still picked since there is less information on safety in pregnancy for cabergoline.
- Lactation suppression
- adjunctive therapy of prolactin-producing pituitary gland tumors (prolactinomas);
- monotherapy of Parkinson’s disease in the early phase;
- combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson’s disease;
- in some countries also: ablactation and dysfunctions associated with hyperprolactinemia (amenorrhea, oligomenorrhea, anovulation, nonpuerperal mastitis, and galactorrhea);
- treatment of uterine fibroids.
- adjunctive therapy of acromegaly, cabergoline has low efficacy in suppressing growth hormone levels and is highly efficient in suppressing hyperprolactinemia that is present in 20-30% of acromegaly cases; growth hormone and prolactin are similar structurally and have similar effects in many target tissues, therefore targeting prolactin may help symptoms when growth hormone secretion cannot be sufficiently controlled by other methods.
Pregnancy and Lactation
Relatively little is known about the effects of this medication during pregnancy and lactation. At times, the related bromocriptine might be an elective when pregnancy is normal.
- Pregnancy: available preliminary data indicates a somewhat increased rate of congenital abnormalities in patients who became pregnant while treated with cabergoline.. However, one study concluded that “fetal exposure to cabergoline through early pregnancy does not induce any increase in the risk of miscarriage or fetal malformation.”
- Lactation: In rats, cabergoline was found in the maternal milk. Since it is not known if this effect also occurs in humans, breastfeeding is usually not recommended if/when treatment with cabergoline is necessary.
- Lactation suppression: In some countries, cabergoline (Dostinex) is sometimes used as a lactation suppressant. It is also used in veterinary medicine to treat false pregnancy in dogs.
- Hypersensitivity to ergot derivatives
- Pediatric patients (no clinical experience)
- Severely impaired liver function or cholestasis
- Co-medication with drugs metabolized mainly by CYP P450 such as erythromycin and ketoconazole, because increased plasma levels of cabergoline may result (although cabergoline undergoes minimal CYP450 metabolism).
- Cautions: severe cardiovascular disease, Raynaud’s disease, gastroduodenal ulcers, active gastrointestinal bleeding, hypotension.
Side effects are mostly dose-dependent. Considerably more extreme reactions are accounted for treatment of Parkinson’s malady and (off-name treatment) for anxious leg disorder which both ordinarily require exceptionally high dosages. The side effects are considered mild when used for the treatment of hyperprolactinemia and other endocrine disorders or gynecologic indications where the typical dose is one hundredth to one-tenth that for Parkinson’s disease.
Cabergoline requires moderate portion titration (2 a month for hyperprolactinemia, regularly any longer for different conditions) to limit symptoms. The incredibly long bioavailability of the medicine may confuse dosing regimens during titration and require specific precautionary measures.
Cabergoline is viewed as the best middle of the road alternative for hyperprolactinemia treatment in spite of the fact that the more up to date and less tried quinagolide may offer a comparatively positive reaction profile with faster titration times.
No interactions were noted with levodopa or selegiline. The medication should not be combined with other ergot derivatives. Dopamine enemies, for example, antipsychotics and metoclopramide neutralize a few impacts of cabergoline. The utilization of antihypertensive medications ought to be seriously checked in light of the fact that exorbitant hypotension may result from the blend.
All of our products are laboratory tested and the results are periodically published on the website.
We are arranging and purchasing in mass from top peptide and research concoction makers from around the globe to bring the end scientist discount limited costs of the most noteworthy
Also known as: 1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea, 1-ethyl-2-(3′-dimethylaminopropyl)-3-(6′-allylergoline-8′-beta-carbonyl)urea diphosphate, Cabaser, Cabaseril, cabergoline, caber, cabergoline diphosphate, Dostinex, FCE 21336, Galastop